Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors

Recurrent Childhood Medulloblastoma Clinical Trial

Official title:

Phase I Study of Intraventricular Infusions of Autologous Ex Vivo-Expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02271711
• Other study ID #: 2013-0765
• Secondary ID: NCI-2014-0267720
• Status: Completed
• Phase: Phase 1
• Start date: March 17, 2015
• Est. completion date: August 28, 2020

Study information

• Verified date: August 2020
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of expanded natural killer cells in treating younger patients with brain tumors that have come back or do not respond to treatment. Infusing a particular type of a patient's own white blood cells called natural killer cells that have been through a procedure to expand (increase) their numbers may work in treating patients with recurrent/refractory brain tumors.

Description:

PRIMARY OBJECTIVES:

I. To establish the safety, feasibility, efficacy, and maximum tolerated dose (MTD) of administering autologous natural killer (NK) cells that have been propagated ex vivo with artificial antigen-presenting cells (aAPC) and administered directly into the ventricle in recurrent /refractory malignant posterior fossa tumors.

SECONDARY OBJECTIVES:

I. To assess the antitumor activity based on imaging and cytology of autologous NK cell locoregional administration directly into the lateral or fourth ventricle.

II. To determine the persistence of adoptively-transferred expanded NK cells (as performed with excess NK cells, via optional correlative studies).

III. Determine the immunophenotype and function of expanded NK cells. IV. Determine the overall response of medulloblastoma to NK-cell therapy. V. Correlate NK cell persistence, phenotype, and function with overall response.

OUTLINE: This is a dose-escalation study.

Patients receive autologous expanded NK cells intravenously (IV) into the ventricle over 3 minutes once weekly on weeks 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may continue treatment at the discretion of the treating physician if pseudo-progression or benefit of slowed progression is suspected.

After completion of study treatment, patients are followed up within 30 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: August 28, 2020
• Est. primary completion date: August 28, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

• Diagnosis: patients with recurrent/refractory medulloblastoma (MB), atypical teratoid (AT)/rhabdoid tumors (RT) or ependymoma involving the brain and/or spine at original diagnosis or relapse; they must have histological verification at diagnosis and/or relapse; patient must have presented with these tumors in the posterior fossa (PF) or relapsed in the PF

• Patient must have either measurable or evaluable tumor

• Presence of or determined by neurosurgery to be a candidate for an implanted catheter in the ventricles to receive NK cell infusion

• Life expectancy of at least 12 weeks in opinion of principal investigator (PI) and/or designee

• Lansky score of 50 or greater if =<16 years of age or a Karnofsky score of 50 or greater if > 16 years of age (NOTE: patients who are unable to walk because of paralysis, but who are in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score)

• Neurologic deficits must have been relatively stable for a minimum of 1 week prior to study enrollment

• Patients must have recovered from the acute toxic effects of all prior anticancer chemotherapy

• Patient must be 4 weeks off any palliative radiation or craniospinal radiation

• Absolute neutrophil count (ANC) of >= 1000/uL

• Platelet count of >= 30,000

• Hemoglobin of >= 9.0 g/dl

• Patients with a seizure disorder may be enrolled if well-controlled and on non-enzyme inducing anticonvulsants

• Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent

Exclusion Criteria:

• Enrolled in another treatment protocol

• Evidence of untreated infection

• Extra-cranial metastasis

• Chronic corticosteroid dependence (except replacement therapy)

• Extensive disease, disease location, and/or co-morbid condition that the PI or designee considers unsafe for surgical intervention of NK cell infusion

• Pregnant or lactating women

Related Conditions & MeSH terms

• Ependymoma
• Medulloblastoma
• Recurrent Childhood Medulloblastoma
• Recurrent Ependymoma
• Recurrent Medulloblastoma

Intervention

Other:
• Laboratory Biomarker Analysis
Correlative studies

Biological:
• Natural Killer Cell Therapy
Given autologous ex-vivo expanded NK cells IV

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD) of natural killer (NK) cells	Defined as the highest dose studied in which 6 patients have been treated at most 1 patient with dose limiting toxicities are observed. Toxicities will be summarized by tabulation in terms of type, grade and attribution for each dose level of each group of patients studied at the end of the trial.	4 weeks
Secondary	Activation status of NK cells	Determined by flow-based activation assay determining cluster of differentiation (CD)107a expression of NK cells in response to standardized targets.	Up to 30 days after the last infusion in course 3
Secondary	Persistence of NK cells	Peripheral blood and cerebrospinal fluid (CSF) will be obtained before therapy, during the NK cell treatment period, and after NK cell treatment.	Up to 30 days after the last infusion in course 3
Secondary	Function of NK cells	Assessed by cell lysis of standardized targets.	Up to 30 days after the last infusion in course 3
Secondary	Response of medulloblastoma to NK cells	Antitumor activity will be described for each group of patients based on imaging and cytology. Clinical response will be correlated with NK cell persistence in vivo, cytokine levels, and expression of activation markers.	Up to 30 days after the last infusion in course 3
Secondary	Feasibility of NK cell manufacturing	If analysis shows < 50% successful product generation after at least six patients have been enrolled, the study will be temporarily stopped to address possible changes in the manufacturing process.	Up to 12 weeks
Secondary	Feasibility of delivering NK cells	Therapy will be considered feasible if at least 2/3 of subjects treated receive at least 21 of the planned 27 NK cell infusions.	Up to 12 weeks

External Links

•   University of Texas MD Anderson Cancer Center Website